Nanobiotix (NBTX) Current Leases (2021 - 2023)

Nanobiotix's (NBTX) quarterly Current Leases came in at $1.2 million in Q2 2023, up 3.86% year-on-year from $1.2 million in Q2 2022, and up 3.86% quarter-over-quarter from $1.2 million in Q2 2022.

Nanobiotix (NBTX) Current Leases (2021 - 2023) Analysis & Trends

Nanobiotix's Current Leases history runs 3 years deep, the most recent figure standing at $1.2 million for Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 531,233.95
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 20.58 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 720.00 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 16.61 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn 45.66 Mn

Historic Data

Download Data
DateValue
Jun 30, 2023 1.25 Mn
Jun 30, 2022 1.20 Mn
Jun 30, 2021 1.44 Mn